CYTX up 7.11% after Director buy reported by InsiderCow.
Rickey David of Cytori Therapeutics, Inc. (Nasdaq: CYTX) bought Shares of CYTX.
Trade amount: 2,000 Shares
Trade type: Open Market Buy
Price Range: 2.44 - 2.68
Transaction details can be found at http://www.insidercow.com/history/company.jsp?company=CYTX Get real-time alert on any insider trading information from www.insidercow.com, one step before everybody else.
InsiderCow.com is a leading real-time insider trading information provider. InsiderCow.com is the online division of InsiderCow, a privately-owned company specialized in insider trading information. InsiderCow uses its proprietary software to gather and analyze information provided by the U.S. Securities and Exchange Commission, in real-time. For more information about InsiderCow.com, visit www.insidercow.com.
Cytori Therapeutics, Inc., a cell therapy company, engages in developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular diseases and other medical conditions. It primarily provides the Celution System, which automates the process of digesting fat tissue, releasing the ADRCs. It also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment, as well as a range of ancillary products designed to optimize tissue harvest and graft delivery.
Disclosure: Insidercow.com is not a registered investment adviser or broker/dealer. Insidercow.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable.
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.